Switchability = IBE [Design Issues]

posted by Achievwin – US, 2022-05-20 14:19 (48 d 03:38 ago) – Posting: # 23007
Views: 277

» population BE (prescribability) and individual BE (switchability) are of historic interest only. Both are not assessed in any of the currently recommended approaches (average BE, reference-scaled BE, average BE with expanding limits).

Thanks for the clarification

I vaguely recall when you don't have subject by formulation interaction in a replicate study design (4-period full replicate design???) you can request switchability (Metadate ANDA I guess)

My question is can we assess this subject by formulation interaction in a 3-period partial replicate design?) what additional statistical test one needs for documenting this?

Complete thread:

UA Flag
Activity
 Admin contact
22,192 posts in 4,651 threads, 1,574 registered users;
online 5 (0 registered, 5 guests [including 2 identified bots]).
Forum time: Thursday 17:57 CEST (Europe/Vienna)

Any sufficiently advanced technology
is indistinguishable from magic.    Arthur C. Clarke

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5